Marker Therapeutics, Inc. (MRKR)
1.26
-0.04
(-3.08%)
USD |
NASDAQ |
Sep 02, 16:00
1.26
0.00 (0.00%)
After-Hours: 20:00
Marker Therapeutics Research and Development Expense (TTM) : 8.806M for June 30, 2026
Research and Development Expense (TTM) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (TTM) Data
| Date | Value |
|---|---|
| June 30, 2026 | 8.806M |
| March 31, 2026 | 11.51M |
| December 31, 2025 | 11.80M |
| September 30, 2025 | 14.74M |
| June 30, 2025 | 15.87M |
| March 31, 2025 | 14.03M |
| December 31, 2024 | 13.47M |
| September 30, 2024 | 11.00M |
| June 30, 2024 | 9.573M |
| March 31, 2024 | 9.615M |
| December 31, 2023 | 10.42M |
| September 30, 2023 | 9.982M |
| June 30, 2023 | 11.53M |
| March 31, 2023 | 15.71M |
| December 31, 2022 | 19.36M |
| September 30, 2022 | 25.19M |
| June 30, 2022 | 28.38M |
| March 31, 2022 | 29.18M |
| December 31, 2021 | 27.79M |
| September 30, 2021 | 25.76M |
| June 30, 2021 | 23.78M |
| March 31, 2021 | 20.71M |
| December 31, 2020 | 18.88M |
| September 30, 2020 | 16.56M |
| June 30, 2020 | 14.87M |
| Date | Value |
|---|---|
| March 31, 2020 | 13.75M |
| December 31, 2019 | 12.76M |
| September 30, 2019 | 127.80M |
| June 30, 2019 | 126.56M |
| March 31, 2019 | 125.23M |
| December 31, 2018 | 124.00M |
| September 30, 2018 | 6.740M |
| June 30, 2018 | 6.486M |
| March 31, 2018 | 5.861M |
| December 31, 2017 | 5.251M |
| September 30, 2017 | 4.272M |
| June 30, 2017 | 3.758M |
| March 31, 2017 | 3.803M |
| December 31, 2016 | 3.80M |
| September 30, 2016 | 3.475M |
| June 30, 2016 | 3.135M |
| March 31, 2016 | 2.088M |
| December 31, 2015 | 1.711M |
| September 30, 2015 | 1.691M |
| June 30, 2015 | 0.9545M |
| March 31, 2015 | 0.7759M |
| December 31, 2014 | 0.189M |
| September 30, 2014 | 0.5204M |
| June 30, 2014 | 0.5179M |
| March 31, 2014 | 0.5498M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (TTM) Benchmarks
| Krystal Biotech, Inc. | 53.39M |
| Ironwood Pharmaceuticals, Inc. | 86.86M |
| SELLAS Life Sciences Group, Inc. | 20.35M |
| Rezolute, Inc. | 59.77M |
| ADMA Biologics, Inc. | 11.52M |